Research Topics
| T B BrunnerSummaryAffiliation: University of Oxford Country: UK Publications
| Collaborators
|
Detail Information
Publications
Progress towards the use of HIV protease inhibitors in cancer therapyEric J Bernhard
Oxford University, Radiation Oncology and Biology, Radiobiology Research Institute, Headington, Oxford, United Kingdom
Cancer Biol Ther 7:636-7. 2008..It is this point that Plasteras et al. address in the current issue of Cancer Biology & Therapy, by examining the effects of combined treatment with radiation and HIV protease inhibitors.(3)...
Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patientsThomas B Brunner
Radiation Oncology of the Friedrich Alexander University of Erlangen Nuremberg, Universitätsstraße 22, 91054 Erlangen, Germany
Radiat Oncol 6:88. 2011..The aim of this retrospective analysis was to evaluate the effect of two concurrent chemoradiotherapy regimens using 5-fluorouracil or gemcitabine to compare their effect and tolerance...
Radiotherapy and chemotherapy as therapeutic strategies in extrahepatic biliary duct carcinomaThomas B Brunner
Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, United Kingdom
Strahlenther Onkol 186:672-80. 2010..this report aims to provide an overview on radiotherapy and chemotherapy in extrahepatic biliary duct carcinoma (BDC)...- The role of radiotherapy in multimodal treatment of pancreatic carcinomaThomas B Brunner
Gray Institute for Radiation Oncology and Biology, University of Oxford, Oxford, UK
Radiat Oncol 5:64. 2010..Whenever possible, radiotherapy should be performed as simultaneous chemoradiotherapy. Patients with PDAC should be offered entry into clinical trials to identify optimal treatment results... - Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancerThomas B Brunner
Gray Institute of Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford, United Kingdom
J Clin Oncol 26:2699-706. 2008..Preclinically, HIV protease inhibitors radiosensitize tumors with activated PI3-kinase/Akt pathway. We determined the toxicity of nelfinavir chemoradiotherapy in borderline resectable and unresectable pancreatic cancer... - Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boostThomas B Brunner
Department of Radiation Therapy, Friedrich Alexander University of Erlangen Nuremberg, Erlangen
Strahlenther Onkol 184:15-22. 2008..To present the results of a prospective phase II study in esophageal carcinoma... - [The role of radiochemotherapy in multimodal therapy of pancreatic cancer]T B Brunner
Dtsch Med Wochenschr 132:808-12. 2007 - Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary WorThomas B Brunner
Department of Radiation Oncology of the University at Erlangen Nuremberg, Erlangen, Germany
BMC Cancer 7:41. 2007..Furthermore, the synopsis of the overall survival results of neoadjuvant trials suggests a higher rate compared to adjuvant trials... - Adjuvant and neoadjuvant radiochemotherapy in ductal pancreatic carcinomaT B Brunner
Department of Radiation Therapy, Friedrich Alexander University Erlangen Nurnberg, Germany
Strahlenther Onkol 176:265-73. 2000..Ductal pancreatic carcinoma ranks third among malignancies of the gastrointestinal tract and its incidence is rising. Today, patients with this disease still have fatal prognosis necessitating efforts towards more effective treatment... - Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patientsThomas B Brunner
Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Universitätstrasse 27, 91054 Erlangen, Germany
Strahlenther Onkol 182:210-5. 2006..The aim of the present study was to retrospectively assess overall survival and toxicity of chemotherapy in addition to chemoradiation in this patient group... - Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysisThomas B Brunner
Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
Strahlenther Onkol 180:751-7. 2004..This study compared stenting and chemoradiation (CRT) and attempted to identify factors that are predictive of response to CRT... - Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planningThomas B Brunner
Department of Radiation Oncology, University Hospitals of Erlangen, Erlangen, Germany
Radiother Oncol 81:190-5. 2006..Lymphatics follow the large vessels of this region. Vascular variability with consequences for planning treatment volume (PTV) was studied... - Radiotherapy in pancreatic cancerGunther Klautke
Department of Radiation Therapy, University of Rostock, Rostock, Germany
Strahlenther Onkol 184:557-64. 2008..Patients with PDAC should always be treated within studies to identify optimal treatment results... - Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysisThomas B Brunner
Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Universitätstrasse 27, 91054 Erlangen Nuremberg, Germany
Int J Radiat Oncol Biol Phys 62:1021-9. 2005..We aimed to define guidelines for elective treatment of nodal areas based on pathologic nodal involvement to optimize treatment volume for this tumor... - Downstaging of pancreatic carcinoma after neoadjuvant chemoradiationDominik Tinkl
Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
Strahlenther Onkol 185:557-66. 2009..This approach was tested in a cohort to estimate its effect on survival... - Adenocarcinoma of the esophagogastric junction: the pattern of metastatic lymph node dissemination as a rationale for elective lymphatic target volume definitionIris Meier
Department of Radiation Oncology, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
Int J Radiat Oncol Biol Phys 70:1408-17. 2008..We aimed to clarify the lymph node (LN) distribution of AEG according to location of the tumor mass and invasion of neighboring areas for the selection of radiotherapy planning target volume (PTV) margins... - Radiation sensitization by inhibition of activated RasThomas B Brunner
Department of Radiation Oncology, University Hospital, Erlangen, Germany
Strahlenther Onkol 180:731-40. 2004..This article reviews preclinical and phase I clinical studies that reported on combining inhibition of activated Ras and downstream effectors of Ras with radiotherapy... - Predictive and prognostic factors in small cell lung carcinoma (SCLC)--analysis from routine clinical practiceWolfgang M Brueckl
Department of Medicine 1, University Hospital Erlangen, Friedrich Alexander University of Erlangen Nuremberg, Erlangen, Germany
Anticancer Res 26:4825-32. 2006..Prognostic and predictive factors of routine clinical practice among patients with small cell lung carcinoma (SCLC) were evaluated... - Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancerThomas B Brunner
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Int J Radiat Oncol Biol Phys 55:144-53. 2003..We used a time-dependent schedule to determine the maximal-tolerated dose and dose-limiting toxicities (DLTs; Grade 4 hematologic or Grade 3 other toxicity)... - Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cellsKeith A Cengel
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
Neoplasia 9:341-8. 2007..Taken together, these findings suggest that EGFR-activated H-Ras signaling is initiated by oncogenic K-Ras to promote radiation survival in pancreatic and colorectal cancers... - A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancerNeil E Martin
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Clin Cancer Res 10:5447-54. 2004..CONCLUSIONS: The combination of L-778,123 and radiotherapy at dose level 1 showed acceptable toxicity in patients with locally advanced pancreatic cancer. Radiosensitization of a patient-derived pancreatic cancer cell line was observed... - Molecular verification of stereotactic radiotherapy in rats using ATMpS1981 immunofluorescenceThomas B Brunner
Department of Radiation Oncology, University Hospitals of Erlangen, Germany
Radiother Oncol 79:109-14. 2006..CONCLUSIONS: ATMpS1981 immunofluorescence confirms accuracy of STS allowing for partial organ irradiation in small animals. It can be used for quality assurance in STS treatment of normal tissue or orthotopic tumor models... - Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigationsThomas B Brunner
Department of Radiation Oncology, University of Pennsylvania, Philadelphia 19104-6072, USA
Cancer Res 63:5656-68. 2003..We conclude that the rational combination of FTIs with other therapies, taking into account the biological activities of the individual agents, may improve the clinical results obtained with FTIs... - Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-RasThomas B Brunner
Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6072, USA
Cancer Res 65:8433-41. 2005..Farnesyltransferase inhibitors could therefore be of use as sensitizers for pancreatic carcinoma radiotherapy...